Technical Analysis for BMRN - BioMarin Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade A 97.6 8.47% 7.62
BMRN closed up 8.47 percent on Friday, June 15, 2018, on 3.42 times normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical BMRN trend table...

Date Alert Name Type % Chg
Jun 15 MACD Bullish Signal Line Cross Bullish 0.00%
Jun 15 Expansion Breakout Bullish Swing Setup 0.00%
Jun 15 Volume Surge Other 0.00%
Jun 15 Wide Range Bar Range Expansion 0.00%
Jun 15 Above Upper BB Strength 0.00%
Jun 15 Upper Bollinger Band Touch Strength 0.00%
Jun 14 Hammer Candlestick Bullish 8.47%
Jun 14 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 8.47%
Jun 14 Cup with Handle Other 8.47%
Jun 14 Multiple of Ten Bearish Other 8.47%

Older signals for BMRN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company's commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It also develops Vimizim, an enzyme replacement therapy that is in phase III clinical stage for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; BMN-673, a clinical Phase I/II trial product for the treatment of cancer; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of BH4 in Kuvan for PKU and for other indications, and PEG-PAL. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.
Is BMRN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 100.03
52 Week Low 75.81
Average Volume 1,378,396
200-Day Moving Average 86.9196
50-Day Moving Average 86.787
20-Day Moving Average 90.6455
10-Day Moving Average 91.443
Average True Range 2.5862
ADX 15.54
+DI 37.56
-DI 15.69
Chandelier Exit (Long, 3 ATRs ) 91.0414
Chandelier Exit (Short, 3 ATRs ) 91.7786
Upper Bollinger Band 94.8683
Lower Bollinger Band 86.4227
Percent B (%b) 1.32
BandWidth 9.317175
MACD Line 1.46
MACD Signal Line 1.3902
MACD Histogram 0.0697
Fundamentals Value
Market Cap 17.1 Billion
Num Shares 175 Million
EPS -1.07
Price-to-Earnings (P/E) Ratio -91.21
Price-to-Sales 12.04
Price-to-Book 5.17
PEG Ratio -4.46
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 110.80
Resistance 3 (R3) 109.73 104.27 108.60
Resistance 2 (R2) 104.27 100.91 104.80 107.87
Resistance 1 (R1) 100.93 98.83 102.60 102.00 107.13
Pivot Point 95.47 95.47 96.30 96.00 95.47
Support 1 (S1) 92.13 92.11 93.80 93.20 88.07
Support 2 (S2) 86.67 90.03 87.20 87.33
Support 3 (S3) 83.33 86.67 86.60
Support 4 (S4) 84.40